← Back to All US Stocks

Foxo Technologies Inc.. (FOXOW) Stock Fundamental Analysis & AI Rating 2026

FOXOW OTC Services-Commercial Physical & Biological Research DE CIK: 0001812360
Updated This Month • Analysis: Mar 25, 2026 • SEC Data: 2025-09-30
Combined AI Rating
STRONG SELL
90% Confidence
STRONG AGREEMENT
STRONG SELL
92% Conf
STRONG SELL
88% Conf

📊 FOXOW Key Takeaways

Revenue: $11.9M
Net Margin: -25.3%
Free Cash Flow: $-3.9M
Current Ratio: 0.15x
Debt/Equity: 0.14x
EPS: $0.00
AI Rating: STRONG SELL with 92% confidence
Foxo Technologies Inc.. (FOXOW) receives a STRONG SELL rating with 90% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $11.9M, net profit margin of -25.3%, and return on equity (ROE) of -14.9%, Foxo Technologies Inc.. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete FOXOW stock analysis for 2026.

Is Foxo Technologies Inc.. (FOXOW) a Good Investment?

Claude

FOXO Technologies demonstrates severe operational distress with massive negative profitability across all metrics, burning cash at an unsustainable rate while generating minimal revenue relative to its cost structure. The company faces critical liquidity constraints with a current ratio of 0.15x and declining financial health, making it unsuitable for fundamental-based investment.

ChatGPT

FOXO Technologies shows deeply impaired fundamentals, with near-break-even gross profit, negative operating and free cash flow, and a very weak liquidity position. While revenue appears stable and leverage is not extreme on a debt-to-equity basis, the business is not converting sales into sustainable earnings or cash generation. The combination of low cash, sub-1.0 current ratio, and continuing losses suggests elevated financial stress unless operating performance improves materially.

Why Buy Foxo Technologies Inc.. Stock? FOXOW Key Strengths

Claude
  • + Positive revenue of $11.9M provides some operational activity base
  • + Moderate debt-to-equity ratio of 0.14x limits leverage risk relative to equity
  • + Substantial asset base of $52.1M suggests prior capitalization
ChatGPT
  • + Revenue was stable year over year, indicating the business has not yet experienced top-line contraction
  • + Debt-to-equity remains relatively modest, limiting balance-sheet strain compared with heavily levered peers
  • + Positive stockholders' equity provides some balance-sheet support despite ongoing losses

FOXOW Stock Risks: Foxo Technologies Inc.. Investment Risks

Claude
  • ! Severely negative net margin of -25.3% indicates operational model is fundamentally unprofitable
  • ! Operating cash flow of -$3.8M with free cash flow of -$3.9M demonstrates unsustainable cash burn with only $628.6K in cash reserves
  • ! Critical liquidity crisis with current ratio of 0.15x—company cannot cover short-term obligations with liquid assets
  • ! Gross margin of only 0.1% on $11.9M revenue suggests either severe underpricing or inefficient cost structure
  • ! Negative ROE of -14.9% and ROA of -5.8% indicate value destruction across all capital deployment
  • ! Net loss of -$3.0M represents 25% of annual revenue, unsustainable trajectory
ChatGPT
  • ! Gross margin of roughly 0.1% indicates extremely weak unit economics and little cushion against operating costs
  • ! Current and quick ratios of 0.15x, along with only about $0.63M of cash, signal significant near-term liquidity risk
  • ! Negative operating cash flow and free cash flow suggest the company may need external funding if performance does not improve

Key Metrics to Watch

Claude
  • * Quarterly operating cash flow trend and cash runway to insolvency
  • * Gross margin improvement and cost structure rationalization efforts
  • * Revenue growth relative to operating expense reduction
ChatGPT
  • * Gross margin and operating margin improvement
  • * Cash balance and operating cash flow trend

Foxo Technologies Inc.. (FOXOW) Financial Metrics & Key Ratios

Revenue
$11.9M
Net Income
$-3.0M
EPS (Diluted)
$0.00
Free Cash Flow
$-3.9M
Total Assets
$52.1M
Cash Position
$628.6K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

FOXOW Profit Margin, ROE & Profitability Analysis

Gross Margin 0.1%
Operating Margin -15.4%
Net Margin -25.3%
ROE -14.9%
ROA -5.8%
FCF Margin -32.4%

FOXOW vs Healthcare Sector: How Foxo Technologies Inc.. Compares

How Foxo Technologies Inc.. compares to Healthcare sector averages

Net Margin
FOXOW -25.3%
vs
Sector Avg 12.0%
FOXOW Sector
ROE
FOXOW -14.9%
vs
Sector Avg 15.0%
FOXOW Sector
Current Ratio
FOXOW 0.1x
vs
Sector Avg 2.0x
FOXOW Sector
Debt/Equity
FOXOW 0.1x
vs
Sector Avg 0.6x
FOXOW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Foxo Technologies Inc.. Stock Overvalued? FOXOW Valuation Analysis 2026

Based on fundamental analysis, Foxo Technologies Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-14.9%
Sector avg: 15%
Net Profit Margin
-25.3%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.14x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Foxo Technologies Inc.. Balance Sheet: FOXOW Debt, Cash & Liquidity

Current Ratio
0.15x
Quick Ratio
0.15x
Debt/Equity
0.14x
Debt/Assets
61.3%
Interest Coverage
-0.65x
Long-term Debt
$2.9M

FOXOW Revenue & Earnings Growth: 5-Year Financial Trend

FOXOW 5-year financial data: Year 2024: Revenue $4.1M, Net Income -$26.5M, EPS N/A. Year 2025: Revenue $16.4M, Net Income -$12.4M, EPS N/A.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Foxo Technologies Inc..'s revenue has grown significantly by 304% over the 5-year period, indicating strong business expansion.

FOXOW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-32.4%
Free cash flow / Revenue

FOXOW Quarterly Earnings & Performance

Quarterly financial performance data for Foxo Technologies Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.2M -$1.9M N/A
Q2 2025 $27.5K -$522.0K N/A
Q1 2025 $7.2K -$616.5K N/A
Q3 2024 $10.0K -$1.9M N/A
Q2 2024 $12.0K -$2.2M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Foxo Technologies Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$3.8M
Cash generated from operations
Stock Buybacks
$29.1M
Shares repurchased (TTM)
Capital Expenditures
$110.0K
Investment in assets
Dividends
None
No dividend program

FOXOW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Foxo Technologies Inc.. (CIK: 0001812360)

📋 Recent SEC Filings

Date Form Document Action
Apr 15, 2026 10-K form10-k.htm View →
Apr 2, 2026 8-K form8-k.htm View →
Mar 24, 2026 8-K form8-k.htm View →
Feb 9, 2026 S-1 forms-1.htm View →
Feb 6, 2026 8-K form8-k.htm View →

Frequently Asked Questions about FOXOW

What is the AI rating for FOXOW?

Foxo Technologies Inc.. (FOXOW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are FOXOW's key strengths?

Claude: Positive revenue of $11.9M provides some operational activity base. Moderate debt-to-equity ratio of 0.14x limits leverage risk relative to equity. ChatGPT: Revenue was stable year over year, indicating the business has not yet experienced top-line contraction. Debt-to-equity remains relatively modest, limiting balance-sheet strain compared with heavily levered peers.

What are the risks of investing in FOXOW?

Claude: Severely negative net margin of -25.3% indicates operational model is fundamentally unprofitable. Operating cash flow of -$3.8M with free cash flow of -$3.9M demonstrates unsustainable cash burn with only $628.6K in cash reserves. ChatGPT: Gross margin of roughly 0.1% indicates extremely weak unit economics and little cushion against operating costs. Current and quick ratios of 0.15x, along with only about $0.63M of cash, signal significant near-term liquidity risk.

What is FOXOW's revenue and growth?

Foxo Technologies Inc.. reported revenue of $11.9M.

Does FOXOW pay dividends?

Foxo Technologies Inc.. does not currently pay dividends.

Where can I find FOXOW SEC filings?

Official SEC filings for Foxo Technologies Inc.. (CIK: 0001812360) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is FOXOW's EPS?

Foxo Technologies Inc.. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is FOXOW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Foxo Technologies Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is FOXOW stock overvalued or undervalued?

Valuation metrics for FOXOW: ROE of -14.9% (sector avg: 15%), net margin of -25.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy FOXOW stock in 2026?

Our dual AI analysis gives Foxo Technologies Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is FOXOW's free cash flow?

Foxo Technologies Inc..'s operating cash flow is $-3.8M, with capital expenditures of $110.0K. FCF margin is -32.4%.

How does FOXOW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -25.3% (avg: 12%), ROE -14.9% (avg: 15%), current ratio 0.15 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 25, 2026 | Data as of: 2025-09-30 | Powered by Claude AI